|
Market Closed -
OTC Markets
15:51:28 2026-06-04 EDT
|
5-day change | 1st Jan Change | ||
| 0.0278 USD | -7.64% |
|
+2.96% | +6.92% |
| 05-18 | Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 11-17 | Adaptimmune Therapeutics plc Announces CEO Changes | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology | 6.15M | 27.15M | 60.28M | 178M | 5.92M | |||||
Total Assets | 470M | 329M | 283M | 246M | 63.36M | |||||
Interest Expense | - | - | - | -3.35M | -7.27M | |||||
Income Tax Expense | 791K | 2.5M | 1.34M | 3.58M | - | |||||
CAPEX | -8.78M | -29.74M | -4.68M | -886K | -388K | |||||
EBT | -157M | -163M | -113M | -67.24M | -78.01M | |||||
Gross Profit | - | - | - | - | 5.92M | |||||
D&A | 6.57M | 6.08M | 9.84M | 11.22M | 11.28M | |||||
Operating Income | -162M | -164M | -140M | -68.76M | -72.57M | |||||
Net Income | -158M | -165M | -114M | -70.81M | 25.21M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United Kingdom | 6.15M | 27.15M | 60.28M | 178M | - | |||||
Total Assets | 29.7M | 42.39M | 40.99M | 24.26M | 16.21M | |||||
Total Assets | 21.67M | 29.15M | 30.72M | 26.95M | 86K |
- Stock Market
- Stocks
- ADAPY Stock
- Financials Adaptimmune Therapeutics plc
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
